MedElevator Войти в исследования
← Поиск публикаций

DOI 10.51821/88.3.14064

Медицинская библиотека · Acta gastro-enterologica Belgica · 2025

Real-world Effectiveness and Safety of Tofacitinib in Multi-Refractory Ulcerative Colitis: insights from a Belgian Cohort with prior Anti-TNF and Vedolizumab Exposure.

Cremer A, Mansour A, Lobaton T, Bossuyt P, Rahier J, Baert F, Dewit O, Macken E, Vijverman A, Van Hootegem P, Mana F, Willandt B, Humblet E, D'Heygere F, Verreth A, El Nawar A, Coenegrachts J, Dewit S, De Coninck S, Schoofs N, Delen S, Dutre J, Thienpont C, Vanden Branden S, Staessen D, Croonen C, Vieujean S, Franchimont D

СтатьяНаблюдательное исследованиеМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND AND AIMS: Tofacitinib has expanded treatment options for moderate-to-severe ulcerative colitis (UC). Longterm real-world data on its efficacy and safety remain limited, particularly in multi-refractory populations. This study evaluated the real-world effectiveness and safety of tofacitinib in Belgian UC patients with prior exposure to anti-TNF and vedolizumab.

PATIENTS AND

METHODS

This retrospective multicentric observational study included consecutive adult UC patients from 26 Belgian centers who initiated tofacitinib through an early access program (November 2018-August 2019). Data were prospectively collected. Primary endpoint was clinical remission (partial adapted Mayo score≤1) at the end of follow-up (predefined as week 52). Secondary endpoints included endoscopic outcomes, treatment retention rate, colectomy-free survival, and adverse events (AEs).

RESULTS

Seventy-five patients (59% men, median age 44 years) were included, with a median treatment duration of 45 weeks (IQR:19-51). At baseline, 96% had prior anti-TNF and 97% antiintegrin exposure, while 56% were on concomitant steroids. Clinical remission was achieved by 43% at the end of follow-up. Endoscopic response and remission were observed in 37% and 9% of patients, respectively. Fecal calprotectin <250μg/g at week 16 predicted clinical remission at the end of follow-up (OR:0.03, p=0.01). Overall, 34 patients (45%) discontinued tofacitinib, primarily due to primary non-response (62%). AEs were reported in 33% of patients, with the most common being arthralgia, respiratory tract infections, and herpes zoster. No major cardiovascular events or opportunistic infections occurred.

CONCLUSION

In a real-world Belgian cohort of multi-refractory UC patients, tofacitinib demonstrated effectiveness in achieving clinical remission by the end of follow-up with no new safety signals identified. These findings support its use in this challenging patient population.

Для цитирования: Cremer A, Mansour A, Lobaton T, Bossuyt P, Rahier J, Baert F, Dewit O, Macken E, Vijverman A, Van Hootegem P, Mana F, Willandt B, Humblet E, D'Heygere F, Verreth A, El Nawar A, Coenegrachts J, Dewit S, De Coninck S, Schoofs N, Delen S, Dutre J, Thienpont C, Vanden Branden S, Staessen D, Croonen C, Vieujean S, Franchimont D. Real-world Effectiveness and Safety of Tofacitinib in Multi-Refractory Ulcerative Colitis: insights from a Belgian Cohort with prior Anti-TNF and Vedolizumab Exposure.. Acta gastro-enterologica Belgica. 2025. DOI: 10.51821/88.3.14064.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.